argenex SE (NASDAQ:ARGX) is DCF Advisers LLC's 3rd Largest Position

Key Points

• DCF Advisers LLC reduced its stake in argenex SE by 28.3%, selling 5,650 shares and now holding 14,350 shares worth approximately $8.5 million.
• FMR LLC increased its investment in argenex by 17.2%, acquiring an additional 824,750 shares, bringing its total holdings to over 5.6 million shares valued at $3.45 billion.
• Analysts have expressed a generally positive outlook for argenex, with 19 analysts rating it as a buy and setting an average target price of $736.81.

DCF Advisers LLC cut its holdings in shares of argenex SE (NASDAQ:ARGX - Free Report) by 28.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,350 shares of the company's stock after selling 5,650 shares during the quarter. argenex comprises 4.1% of DCF Advisers LLC's investment portfolio, making the stock its 3rd biggest position. DCF Advisers LLC's holdings in argenex were worth $8,493,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. GeoWealth Management LLC grew its holdings in shares of argenex by 56.3% in the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after purchasing an additional 18 shares in the last quarter. Rakuten Securities Inc. lifted its stake in argenex by 56.4% in the first quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock worth $36,000 after acquiring an additional 22 shares during the last quarter. FIL Ltd purchased a new position in argenex in the fourth quarter worth approximately $38,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in argenex in the fourth quarter worth approximately $38,000. Finally, Golden State Wealth Management LLC purchased a new position in argenex in the first quarter worth approximately $44,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ARGX has been the subject of several research reports. HC Wainwright upped their price target on shares of argenex from $720.00 to $774.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Wedbush restated an "outperform" rating and set a $715.00 price objective on shares of argenex in a research report on Monday, July 21st. Deutsche Bank Aktiengesellschaft raised shares of argenex from a "hold" rating to a "buy" rating in a research note on Tuesday, July 8th. JPMorgan Chase & Co. increased their price objective on shares of argenex from $775.00 to $830.00 and gave the company an "overweight" rating in a research note on Monday. Finally, Guggenheim raised their price target on shares of argenex from $1,060.00 to $1,070.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Eighteen research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $746.81.

argenex Trading Down 0.6%

argenex stock traded down $3.90 during mid-day trading on Thursday, reaching $669.25. The company's stock had a trading volume of 81,246 shares, compared to its average volume of 373,818. The business has a 50 day moving average price of $577.01 and a 200-day moving average price of $597.71. The firm has a market cap of $40.96 billion, a price-to-earnings ratio of 34.32, a PEG ratio of 0.80 and a beta of 0.39. argenex SE has a twelve month low of $500.24 and a twelve month high of $696.21.

argenex (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $3.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.90. The firm had revenue of $866.79 million for the quarter, compared to analyst estimates of $776.82 million. argenex had a return on equity of 21.06% and a net margin of 40.98%. On average, equities analysts expect that argenex SE will post 3.13 EPS for the current fiscal year.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.